Intravenous thrombolysis in acute ischaemic stroke patients with concomitant cancer yielded similar 3-month independence rates compared to patients without cancer (60% vs 55%; p=0.54).
Cohort (n=535)
Yes
Does concomitant neoplastic disease worsen outcomes or increase bleeding risk in acute ischaemic stroke patients treated with intravenous thrombolysis?
Absolute Event Rate: 60% vs 55%
p-value: p=0.54
BACKGROUND: Ischaemic stroke (IS), brain haemorrhage and cerebral venous thrombosis can occur as an early and late complication of cancer in the clinical course. Cancer patients are at increased risk for stroke from direct and indirect effects of their malignancy. AIMS: The aim of our study was to evaluate the relationship between neoplastic disease and the long-term outcome, mortality and the presence of haemorrhagic complications in patients with acute IS treated with i.v. thrombolysis. METHODS: We retrospectively evaluated the demographic and clinical data of 495 Caucasian patients with acute IS and 40 patients with IS and concomitant neoplastic disease who were consecutively treated from 2006 to 2013 in two experienced stroke centres. RESULTS: In analysed group, there were 7.8% of patients with cancer 50.0% male, mean age 72.3 ± 9.3; National Institutes of Health Stroke Scale - 13 (range 9.5-17). Cancer was diagnosed before i.v.-thrombolysis in 28 (70.0%) patients. After 3 months of follow up, 60% of patients were independent (mRS 0-2) compared with the group of patients without cancer - 55% (p = 0.54), 17.5% died (18.4%; p = 0.89), 12.4% suffered haemorrhagic transformation (HT) (17.6%; p = 0.41) and 2.5% experienced SICH (4.4%; p = 0.56, respectively). Other clinical complications were not found. A multivariate analysis showed no impact of neoplastic disease on unfavourable outcomes modified Rankin scale 3-6) after 3 months (p = 0.15). CONCLUSION: Intravenous thrombolysis performed in Caucasian stroke patients with past or current neoplastic diseases, but not in the course of chemo- and radiotherapy, can be a safe and effective method of treatment. In making decision on the thrombolytic treatment, the risk of bleeding complications and the life expectancy should be assessed.
Sobolewski et al. (Fri,) conducted a cohort in Acute ischaemic stroke (n=535). Intravenous thrombolysis in patients with cancer vs. Patients without cancer was evaluated on Independence (mRS 0-2) at 3 months (p=0.54). Intravenous thrombolysis in acute ischaemic stroke patients with concomitant cancer yielded similar 3-month independence rates compared to patients without cancer (60% vs 55%; p=0.54).